Hims & Hers Health (NYSE:HIMS) Given New $60.00 Price Target at BTIG Research

Hims & Hers Health (NYSE:HIMS) had its target price lowered by BTIG Research from $85.00 to $60.00 in a research note released on Monday morning, Marketbeat reports. The firm currently has a buy rating on the stock.

A number of other research analysts also recently weighed in on HIMS. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Bank of America boosted their price objective on Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a report on Tuesday, November 4th. UBS Group set a $32.00 target price on Hims & Hers Health in a report on Tuesday, November 4th. Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a research report on Monday, January 5th. Finally, Leerink Partners upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have issued a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and a consensus target price of $42.62.

Hims & Hers Health Stock Down 2.4%

Hims & Hers Health stock opened at $26.45 on Monday. The company has a market capitalization of $6.02 billion, a PE ratio of 48.97, a PEG ratio of 4.46 and a beta of 2.43. Hims & Hers Health has a 12-month low of $23.97 and a 12-month high of $72.98. The firm’s fifty day moving average is $34.11 and its 200 day moving average is $44.09. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. During the same period last year, the firm posted $0.32 earnings per share. The company’s revenue for the quarter was up 49.2% on a year-over-year basis. As a group, sell-side analysts predict that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Hims & Hers Health announced that its board has initiated a stock buyback program on Monday, November 17th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to buy up to 3% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling

In other Hims & Hers Health news, insider Irene Becklund sold 8,411 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the transaction, the insider owned 2,126 shares of the company’s stock, valued at $78,045.46. This trade represents a 79.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Patrick Harrison Carroll sold 10,021 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $367,870.91. Following the completion of the transaction, the insider owned 169,940 shares in the company, valued at $6,238,497.40. The trade was a 5.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 131,974 shares of company stock valued at $4,763,800 over the last 90 days. 17.71% of the stock is currently owned by company insiders.

Institutional Trading of Hims & Hers Health

A number of hedge funds have recently bought and sold shares of HIMS. Quent Capital LLC bought a new position in Hims & Hers Health in the 3rd quarter valued at $28,000. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health in the 3rd quarter worth about $28,000. Virtus Advisers LLC bought a new position in Hims & Hers Health during the second quarter valued at about $26,000. Quaker Wealth Management LLC bought a new position in Hims & Hers Health during the second quarter valued at about $29,000. Finally, Bessemer Group Inc. increased its holdings in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after buying an additional 312 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.